Metagenomi (MGX) Competitors $1.86 -0.19 (-9.27%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$1.96 +0.10 (+5.11%) As of 03/3/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends MGX vs. TRVI, TSHA, ATYR, TERN, TRML, ACB, CYRX, ATAI, GOSS, and FHTXShould you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Trevi Therapeutics (TRVI), Taysha Gene Therapies (TSHA), Atyr PHARMA (ATYR), Terns Pharmaceuticals (TERN), Tourmaline Bio (TRML), Aurora Cannabis (ACB), Cryoport (CYRX), Atai Life Sciences (ATAI), Gossamer Bio (GOSS), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry. Metagenomi vs. Trevi Therapeutics Taysha Gene Therapies Atyr PHARMA Terns Pharmaceuticals Tourmaline Bio Aurora Cannabis Cryoport Atai Life Sciences Gossamer Bio Foghorn Therapeutics Metagenomi (NASDAQ:MGX) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and community ranking. Is MGX or TRVI more profitable? Trevi Therapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -134.27%. Metagenomi's return on equity of -43.23% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Metagenomi-134.27% -43.23% -18.86% Trevi Therapeutics N/A -63.31%-57.06% Which has stronger valuation and earnings, MGX or TRVI? Trevi Therapeutics has lower revenue, but higher earnings than Metagenomi. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetagenomi$55.08M1.26-$68.25MN/AN/ATrevi TherapeuticsN/AN/A-$29.07M-$0.44-9.68 Do institutionals & insiders hold more shares of MGX or TRVI? 95.8% of Trevi Therapeutics shares are owned by institutional investors. 24.4% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in MGX or TRVI? Trevi Therapeutics received 77 more outperform votes than Metagenomi when rated by MarketBeat users. However, 95.00% of users gave Metagenomi an outperform vote while only 65.75% of users gave Trevi Therapeutics an outperform vote. CompanyUnderperformOutperformMetagenomiOutperform Votes1995.00% Underperform Votes15.00%Trevi TherapeuticsOutperform Votes9665.75% Underperform Votes5034.25% Do analysts prefer MGX or TRVI? Metagenomi currently has a consensus target price of $16.67, suggesting a potential upside of 796.06%. Trevi Therapeutics has a consensus target price of $9.31, suggesting a potential upside of 118.60%. Given Metagenomi's higher probable upside, equities research analysts plainly believe Metagenomi is more favorable than Trevi Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 Does the media refer more to MGX or TRVI? In the previous week, Trevi Therapeutics had 4 more articles in the media than Metagenomi. MarketBeat recorded 6 mentions for Trevi Therapeutics and 2 mentions for Metagenomi. Metagenomi's average media sentiment score of 1.43 beat Trevi Therapeutics' score of 0.31 indicating that Metagenomi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryTrevi Therapeutics beats Metagenomi on 9 of the 15 factors compared between the two stocks. Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGX vs. The Competition Export to ExcelMetricMetagenomiBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.61M$3.08B$5.81B$8.39BDividend YieldN/A1.51%4.75%3.98%P/E RatioN/A28.6624.9519.25Price / Sales1.26403.91375.54110.22Price / CashN/A168.6838.0534.58Price / BookN/A3.487.334.28Net Income-$68.25M-$71.55M$3.18B$247.04M7 Day Performance-20.17%-6.66%-4.42%-4.36%1 Month Performance-25.90%-9.02%-6.07%-5.60%1 Year Performance-84.50%-22.49%11.42%3.38% Metagenomi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGXMetagenomi2.1765 of 5 stars$1.86-9.3%$16.67+796.1%-84.5%$69.61M$55.08M0.00236Positive NewsTRVITrevi Therapeutics3.0129 of 5 stars$4.41-4.2%$9.31+111.4%+45.4%$338.61MN/A-10.0120Gap UpTSHATaysha Gene Therapies2.474 of 5 stars$1.65+2.2%$6.63+302.7%-49.8%$337.13M$15.45M2.61180Earnings ReportAnalyst RevisionATYRAtyr PHARMA2.6741 of 5 stars$4.00-7.5%$18.60+365.6%N/A$335.51M$350,000.00-4.2553TERNTerns Pharmaceuticals4.5915 of 5 stars$3.90-2.9%$18.30+369.8%-53.6%$329.99MN/A-3.2940TRMLTourmaline Bio2.4298 of 5 stars$12.29+0.7%$54.67+344.8%-71.0%$315.20MN/A-4.3644Gap UpACBAurora Cannabis1.2616 of 5 stars$5.71-3.0%N/A+53.0%$313.51M$320.81M114.321,073CYRXCryoport2.3203 of 5 stars$6.32+1.5%$12.29+94.5%-73.2%$313.39M$226.11M-1.881,170ATAIAtai Life Sciences3.1203 of 5 stars$1.82-8.8%$9.00+395.9%-29.6%$304.56M$331,000.00-2.2480GOSSGossamer Bio4.2952 of 5 stars$1.33-5.4%$9.20+594.3%-14.5%$300.25MN/A-4.14180News CoverageFHTXFoghorn Therapeutics2.3526 of 5 stars$5.23+0.1%$13.17+151.6%-45.6%$290.90M$34.15M-2.72120Upcoming Earnings Related Companies and Tools Related Companies Trevi Therapeutics Competitors Taysha Gene Therapies Competitors Atyr PHARMA Competitors Terns Pharmaceuticals Competitors Tourmaline Bio Competitors Aurora Cannabis Competitors Cryoport Competitors Atai Life Sciences Competitors Gossamer Bio Competitors Foghorn Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MGX) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
